Introduction
Pancreatic cancer is currently the fifth leading cause of cancerrelated deaths in Japan. Its mortality is similar to its incidence rate, and the 5-year survival rate of resected cases remains only 15%-20%. [1] [2] [3] [4] Several recent studies have identified high preoperative body fat as a risk factor for intra-abdominal complications, 5, 6 pancreatic fistulas, 7 wound infections, 6 and even decreased overall survival, 8 although other studies have found no such differences. 8, 9 In contrast, low body fat or tumor-associated cachexia may also be associated with increased perioperative complications, mortality, and impaired survival. 8, 10 The role of preoperative nutrition status in pancreatic cancer patients thus remains controversial.
Impaired endocrine and exocrine pancreatic functions induce poor nutrition status in pancreatic cancer patients, while body weight loss in patients with advanced pancreatic cancer during chemoradiation therapy may contribute to poorer survival. 11 In addition, nutrition status decreases after surgery in patients 520992P ENXXX10.1177/0148607114520992Journal of Parenteral and Enteral NutritionHashimoto et al research-article2014 undergoing pancreatectomy and is then expected to recover. 12 These findings suggest that impaired postoperative nutrition status in pancreatic cancer patients may influence prognosis.
This study aimed to assess the effects of postoperative body weight changes on long-term postoperative survival in patients with pancreatic cancer.
Patients and Methods

Patients
A total of 93 patients underwent pancreaticoduodenectomy (PD), distal pancreatectomy (DP), or total pancreatectomy (TP) for primary pancreatic cancer at the Department of Gastroenterological Surgery, Kumamoto University Hospital, between April 2005 and December 2011. Written informed consent was obtained from all patients before treatment. D2 and middle para-aortic lymph node dissection was performed. 13 Combined resection of the vein and reconstruction was performed in patients with possible portal vein (PV)/superior mesenteric vein (SMV) invasion. A feeding tube was placed at the time of operation and removed 3 weeks later, after which patients received a normal diet with no nutrition support. All pre-and postoperative parameters were collected in a prospective electronic database. Patients were evaluated every 1-2 months postoperatively by physical examination, including measurement of body weight, and every 3 months by computed tomography. Evaluations were reduced to 4-to 6-month intervals in patients with no evidence of disease after 2 years of follow-up. All patients evaluated during the study period had a minimum of 5 years follow-up, except for those who died within 5 years of their date of diagnosis. The study protocol was approved by the Institutional Review Board of Kumamoto University Hospital.
Statistical Analysis
Data were analyzed using SAS software (Release 9.1, SAS Institute Inc, Cary, NC). Preoperative body mass index (BMI) was categorized as underweight (<20 kg/m . Parameters were compared between patient subgroups using Mann-Whitney U tests. Overall survival was defined as the time from the date of pancreatic resection to either death from any cause or last follow-up. Patients alive at the last follow-up were censored. Survival rates were calculated using the Kaplan-Meier method, and statistical significance was determined by the log-rank test. Cox proportional hazards models were used for univariate and multivariate analyses of prognosis. Differences were considered statistically significant at P < .05.
Results
Patient and Tumor Characteristics
Patient and tumor characteristics are shown in Table 1 . Among the total of 93 patients, 44 (47.3%) were male and 49 (52.7%) were female. The median age of the study cohort was 69 (41-85) years. Preoperative comorbidities (cardiac, pulmonary, and/ or diabetes mellitus) were present in 39 patients (41.9%). The locations of the primary pancreatic tumor were the pancreas head in 57 patients (61.3%), body in 20 (21.5%), and tail in 16 (17.2%). Fifty-four patients underwent PD (58.1%), 36 underwent DP (38.7%), and 3 underwent TP (3.2%). Among the patients who underwent PD, subtotal stomach-preserving PD was performed in 45 (83.3%), pylorus-preserving PD in 7 (13.0%), and classic PD in 2 (3.7%). Combined resection of the PV/SMV and reconstruction were performed in 20 patients (21.5%). R0 resection was achieved in 78 patients (83.9%) but not in 15 (16.1%, R1 resection). Tumor stage according to the American Joint Committee on Cancer (AJCC) was IA in 13 patients (14.0%), IB in 5 (5.4%), IIA in 25 (26.9%), IIB in 47 (50.5%), and III in 3 (3.2%). Postoperative complications, defined as grade IIIa or above according to the Clavien scale or grade B or C postoperative pancreatic fistulas according to the International Study Group (ISGPF) definition, 14, 15 occurred in 33 (35.5%) patients. Adjuvant chemotherapy was completed in 75 (80.6%) patients. The median survival was 30.3 (12.4-41.4) months, with 1-, 3-, and 5-year overall survivals of 79%, 36%, and 24%, respectively. There were 2 (2.2%) deaths due to causes other than pancreatic cancer (pneumonia and cholangitis).
Overall Survival According to Preoperative BMI
The median preoperative BMI was 22.1 (15.8-30.9) kg/m 2 . Twenty-two patients (23.7%) were underweight, 48 (51.6%) were normal weight, and 23 (24.7%) were overweight. There was no significant association between overall survival and preoperative BMI class (P = .058, Figure 1 ).
Postoperative Body Weight Changes
The overall median postoperative body weight change was −8.4% (−27.4% to +5.5%) at 2 months after surgery, excluding 1 patient who died within 2 months. There were no significant differences in body weight changes according to operative procedures (Figure 2a) or cancer stage (Figure 2b) . The overall median postoperative body weight change at 4 months after surgery was −9.0% (−26.1% to +5.8%), excluding 2 patients who died within 4 months. Similarly, there were no significant differences in body weight changes according to operative procedures (Figure 2c ) or cancer stage (Figure 2d ).
Overall Survival According to Postoperative Body Weight Changes
Patients with severe postoperative body weight loss (<−8.4%, n = 46) at 2 months after surgery showed significantly shorter survival (P = .033; hazard ratio [HR] = 1.82; 95% confidence interval [CI], 1.04-3.19) than patients with mild postoperative body weight loss (>−8.4%, n = 46) (Figure 3a) . Additionally, patients with severe postoperative body weight loss (<−9.0%, n = 45) at 4 months after surgery showed significantly shorter survival (P = .014; HR = 1.99; 95% CI, 1.13-3.48) than patients with mild postoperative body weight loss (>−9.0%, n = 46) (Figure 3b ). Severe postoperative body weight loss was therefore significantly associated with poor prognosis.
Postoperative Body Weight Changes and Survival According to Cancer Stage
Correlations between cancer stage and postoperative body weight changes were analyzed among patients with stage IA-IIA (n = 43) and stage IIB-III (n = 50) pancreatic cancer.
In patients with stage IA-IIA cancer, the median postoperative body weight change was −6.3% (−20.7% to 0%) at 2 months after surgery, excluding 1 patient who died within 2 months. Patients with severe postoperative body weight loss (<−6.3%, n = 21) showed significant shorter survival (P = .005; HR = 3.91; 95% CI, 1.43-10.67) than patients with mild postoperative body weight loss (>−6.3%, n = 21) (Figure 4a ). The median postoperative body weight change at 4 months after surgery was −7.8% (−21.3% to +1.4%), excluding 2 patients who died within 4 months. Similarly, patients with severe postoperative body weight loss (<−7.8%, n = 21) showed significantly shorter survival (P < .001; HR = 6.24; 95% CI, 2.18-17.93) than did patients with mild postoperative body weight loss (>−7.8%, n = 20) (Figure 4b) .
The median postoperative body weight change in patients with stage IIB-III pancreatic cancer was −10.0% (−27.4% to +5.5%) at 2 months after surgery. Patients with severe postoperative body weight loss (<−10.0%, n = 25) tended to have shorter survival than patients with mild postoperative body weight loss (>−10.0%, n = 25), although the difference was not significant (P = .089; HR = 1.83; 95% CI, 0.90-3.70) ( Figure  5a ). The median postoperative body weight change in these patients at 4 months after surgery was −9.3% (−26.1% to +5.8%). Similarly, patients with severe postoperative body weight loss (<−9.3%, n = 25) tended to show shorter survival than patients with mild postoperative body weight loss (>−9.3%, n = 25), although the difference was not significant (P = .109; HR = 1.76; 95% CI, 0.87-3.55), (Figure 5b) .
Severe postoperative body weight loss was thus significantly associated with poor prognosis in patients with pancreatic cancer overall, especially in patients with stage IA-IIA tumors but not in patients with stage IIB-III tumors. 
Univariate and Multivariate Analyses of Overall Survival
Univariate analysis revealed that the presence of comorbidities, AJCC stage (IIB-III), adjuvant chemotherapy, and body weight change at 4 months after surgery (<−9.0%) were significantly related to poor prognosis (Table 2 ). Multivariate analysis of these variables revealed that AJCC stage (IIB-III), adjuvant chemotherapy, and body weight change at 4 months after surgery (<−9.0%) were independent prognostic factors.
Discussion
Obesity is generally regarded as a serious health problem. High BMI has been identified as a risk factor for cardiovascular disease and diabetes [16] [17] [18] and for developing various malignancies. [19] [20] [21] In addition, obesity increased operative morbidity and mortality in patients undergoing pancreatic surgery. 22, 23 However, the role of preoperative BMI in morbidity and mortality in pancreatic cancer patients remains unclear. 2, 9, 10, [24] [25] [26] In the current study, preoperative BMI had no significant effect on long-term survival and was not identified as an independent prognostic factor in multivariate analysis, although survival tended to be related to preoperative BMI. However, one of the limitations of this study was the small sample size. It is difficult to detect a correlation between preoperative nutrition status and outcome in pancreatic cancer patients, because weight loss is frequently associated with pancreatic cancer, and it is therefore difficult to assess patients' usual weight. 9, 11 Further studies with more patients are needed to confirm the correlation between preoperative BMI and survival in patients with pancreatic cancer.
The current results indicated that patients with severe postoperative body weight loss had significantly poorer prognoses after pancreatectomy, whereas there were no significant differences according to operative procedures or cancer stages. Multivariate analysis revealed postoperative body weight loss, cancer stage, and adjuvant chemotherapy as independent prognostic factors. Severe weight loss was considered to be the result of malnutrition. Because pancreatic cancer progression was the cause of death in most (97.8%) cases in the present study, it is possible that malnutrition may contribute to cancer progression or to the failure of adjuvant chemotherapy. Consistent with these results, concerns have been expressed Kaplan-Meier analysis according to postoperative body weight changes at 4 months after surgery categorized as <−9.3% (n = 25) and >−9.3% (n = 25). Differences were considered statistically significant at P < .05. regarding the extent of impaired endocrine and exocrine pancreatic functions after pancreatectomy. 12 Body weight and other aspects of nutrition status are reduced after pancreatectomy and subsequently recover, while malignant disease itself has a significant impact on nutrition status. 12 In addition, weight loss may contribute to poorer survival in patients with inoperable, locally advanced pancreatic cancer. 11 Body weight changes were more severe in patients with stage IIB-III compared with those with stage IA-IIA cancer, although these differences were not significant. This suggests that cancer-related factors have a greater impact on survival in advanced stages, compared with patient-related parameters.
In conclusion, the results of this study indicate that pancreatic cancer patients who experience severe postoperative body weight loss have poorer outcomes after pancreatectomies. This suggests that postoperative long-term nutrition support, such as an elemental diet, may help to improve the prognosis in patients undergoing resection for pancreatic cancer.
